Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 3/20 | 0.43 |
| ▸ | IDO1 | P14902 | 6/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25084330 | 0.83 | KRAS (0.51) | SMN1; SMN2GAAKRASIDO1LMNA | |
| SCHEMBL29545410 | 0.82 | KRAS (0.50) | SMN1; SMN2GAAKRASIDO1LMNA | |
| SCHEMBL17023679 | 0.82 | KRAS (0.50) | SMN1; SMN2GAAKRASIDO1LMNA | |
| SCHEMBL18555583 | 0.81 | KRAS (0.49) | SMN1; SMN2GAAKRASIDO1LMNA | |
| SCHEMBL29545450 | 0.81 | KRAS (0.49) | SMN1; SMN2GAAKRASIDO1LMNA | |
| SCHEMBL19208218 | 0.80 | SMN1; SMN2 (0.69) | SMN1; SMN2GAAKRASKMT2ANPSR1 | |
| SCHEMBL18591258 | 0.79 | KDM4E (0.36) | SYKMEN1KMT2A | |
| SCHEMBL18555476 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2GAAKRASLMNASYK | |
| SCHEMBL17023368 | 0.75 | KRAS (0.41) | SMN1; SMN2GAAKRASIDO1LMNA | |
| SCHEMBL29869185 | 0.75 | KRAS (0.41) | SMN1; SMN2GAAKRASIDO1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-09-14 | — | — | US | disclosed |
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170066783-A1 | Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders | CFD, F12, F3 | SMN1; SMN2 2468/4885GAA 2150/4885KRAS 521/4885 |
| US-20230287005-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, F12, F3 | SMN1; SMN2 2201/4885GAA 2023/4885KRAS 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.